Pneumology - Original Articles Open access

Circulating poly(ADP-ribose) levels in lung cancer: an exploratory study

Authors

Published
13 November 2026
Issue
Early Access
Section
Pneumology - Original Articles
DOI
10.4081/monaldi.2026.4348

Abstract

Poly(ADP-ribose) (PAR) is a polymer generated during poly(ADP-ribosyl)ation, a post-translational modification involved in cellular stress responses and DNA repair. Although PAR-related pathways have been investigated in cancer biology, the clinical significance of circulating PAR levels in patients with lung cancer remains insufficiently characterized. With this study, we investigate the serum levels of PAR in patients with lung cancer and compare them with healthy individuals to assess its potential role as a prognostic biomarker. Serum samples from 23 patients with primary lung cancer who had not received prior cancer treatment and 21 healthy controls were analyzed using a commercial ELISA-based assay. Group differences were evaluated, including an analysis adjusted for age. Our findings demonstrated that the mean serum PAR levels in lung cancer patients were approximately twofold higher compared to the control group (p<0.05). The elevated PAR levels observed in lung cancer patients suggest an upregulation of poly ADP-ribosylation activity, possibly as a response to increased genomic instability and cellular stress associated with tumor progression. This finding supports the hypothesis that PAR metabolism is actively involved in lung carcinogenesis and may serve as a valuable biomarker in evaluating disease prognosis. Our results indicate that PAR levels are significantly elevated in the serum of lung cancer patients compared to healthy individuals. However, the results do not establish the diagnostic accuracy, prognostic value, treatment-predictive capacity, or clinical utility of circulating PAR. Larger, well-characterized prospective studies incorporating clinical and molecular data and serial measurements are needed to validate this observation.

Keywords

Ethics Approval

The study protocol was approved by the Ethical Review Committee of the University of Duzce Health Science Assoc. (protocol no. 192 dated 2025/11/10).

References

  1. Thandra KC, Barsouk A, Saginala K, et al. Epidemiology of lung cancer. Contemp Oncol 2021;25:45-52. DOI: https://doi.org/10.5114/wo.2021.103829
  2. Zhang Y, Wang DC, Shi L, et al. Genome analyses identify the genetic modification of lung cancer subtypes. Semin Cancer Biol 2017;42:20-30. DOI: https://doi.org/10.1016/j.semcancer.2016.11.005
  3. Liu Q, van der Marel GA, Filippov DV- Chemical ADP-ribosylation: mono-ADPr-peptides and oligo-ADP-ribose. Org Biomol Chem 2019;17:5460-74. DOI: https://doi.org/10.1039/C9OB00501C
  4. Aimi F, Moch H, Schraml P, Hottiger MO. Cytoplasmic ADP-ribosylation levels correlate with markers of patient outcome in distinct human cancers. Mod Pathol 2021;34:1468-77. DOI: https://doi.org/10.1038/s41379-021-00788-9
  5. Albert JM, Cao C, Kim KW, et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 2007;13:3033-42. DOI: https://doi.org/10.1158/1078-0432.CCR-06-2872
  6. Guo MZ, Marrone KA, Spira A, Scott SC, et al. Poly(ADP-Ribose) polymerase inhibition in small cell lung cancer: a review. Cancer J 2021;27:476-81. DOI: https://doi.org/10.1097/PPO.0000000000000555
  7. Barayan R, Ran X, Lok BH, et al. PARP inhibitors for small cell lung cancer and their potential for integration into current treatment approaches, J Thorac Dis 2020;12:6240-52. DOI: https://doi.org/10.21037/jtd.2020.03.89
  8. Olivares-Hernández A, Roldán-Ruiz J, Miramontes-González JP, et al. Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis. Chin Clin Oncol 2023:12:62. DOI: https://doi.org/10.21037/cco-23-58
  9. Poltronieri P, Miwa M, Mautani M. ADP-ribosylation as post-translational modification of proteins: use of inhibitors in cancer control. Int J Mol Sci 2021:22:10829. DOI: https://doi.org/10.3390/ijms221910829
  10. Ummarino S, Hausman C, Di Ruscio A. The PARP way to epigenetic changes. Genes 2021;12:446. DOI: https://doi.org/10.3390/genes12030446
  11. Fernandes MP, Oliveira C, Sousa H, Oiveira J. New approaches in early-stage NSCL management: potential use of PARP inhibitors and immunotherapy combination. Int J Mol Sci 2023;24:4044. DOI: https://doi.org/10.3390/ijms24044044
  12. Liu L, Chen G, Gong S, et al. Targeting tumor-associated macrophage: an adjuvant strategy for lung cancer therapy. Front Immunol 2023;14:1274547. DOI: https://doi.org/10.3389/fimmu.2023.1274547
  13. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49. DOI: https://doi.org/10.3322/caac.21660
  14. Lahiri A, Maji A, Potdar PD, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer 2023;22:40. DOI: https://doi.org/10.1186/s12943-023-01740-y
  15. Freeman B, Mamallapalli J, Bian T, et al. Opportunities and challenges of Kava in lung cancer prevention. Int J Mol Sci 2023;24:9539. DOI: https://doi.org/10.3390/ijms24119539
  16. Politi K, Herbst RS. Lung cancer in the era of precision medicine. Clin Cancer Res 2015;21:2213-20. DOI: https://doi.org/10.1158/1078-0432.CCR-14-2748
  17. Gupte R, Liu Z, Kraus WL. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. Genes Dev 2017;31:101-26. DOI: https://doi.org/10.1101/gad.291518.116
  18. Dulaney C, Marcrom S, Stanley J, Yang ES. Poly(ADP-ribose) polymerase activity and inhibition in cancer. Semin Cell Dev Biol 2017;63:144-53. DOI: https://doi.org/10.1016/j.semcdb.2017.01.007
  19. Do K, Chen AP. Molecular pathways: targeting PARP in cancer treatment. Clin Cancer Res 2013;19:977-84. DOI: https://doi.org/10.1158/1078-0432.CCR-12-0163
  20. Yang G, Chen Y, Wu J, et al. Poly(ADP-ribosyl)ation mediates early phase histone eviction at DNA lesions. Nucleic Acids Res 2020;48:3001-13. DOI: https://doi.org/10.1093/nar/gkaa022
  21. Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol 2012;13:411-24. DOI: https://doi.org/10.1038/nrm3376
  22. Kim DS, Challa S, Jones A, Kraus WL. PARPs and ADP-ribosylation in RNA biology: From RNA expression and processing to protein translation and proteostasis. Genes Dev 2020;34:302-20. DOI: https://doi.org/10.1101/gad.334433.119
  23. Martin-Hernandez K, Rodriguez-Vargas JM, Schreiber V, Dantzer F. Expanding functions of ADP-ribosylation in the maintenance of genome integrity. Semin Cell Dev Biol 2017;63:92-101. DOI: https://doi.org/10.1016/j.semcdb.2016.09.009

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2026 The Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.